pSivida (Nasdaq: PSDV) announces positive results from the 36 Month readout of completed Phase 3 FAME study of ILUVIEN® in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE